Skip to main content
. 2018 Dec 21;24(47):5403–5414. doi: 10.3748/wjg.v24.i47.5403

Table 5.

Comparison of patients’ characteristics by age

Valid No. Below 60 yr
 Above 60 yr
 P value
Number % Number %
Patients 111 111 35 31.52 76 68.5
Male gender 111 47 15 42.93 32 42.1 0.941
Ambulatory 111 78 30 85.73 48 63.2 0.011
CDI risk factors
Prior hospitalization 111 80 22 62.93 58 76.3 0.142
Antibiotics use 108 89 28 80.03 61 83.6 0.649
PPI usage 110 37 9 25.73 28 37.3 0.230
Chemotherapy 111 19 7 20.03 12 15.8 0.584
IBD 111 20 14 40.03 6 7.9 0.000
Steroid usage 111 17 9 25.73 8 10.5 0.039
Fever 76 21 7 35.03 14 25.0 0.391
Severe 111 20 3 8.63 17 22.4 0.079
Route
Lower GI 111 50 12 34.33 38 50.0 0.254
Upper GI1 111 24 8 22.93 16 21.1
Capsules 111 37 15 42.93 22 28.9
0-1 Previous CDI 107 24 8 22.93 16 22.2 0.941
2+ previous CDI 107 83 27 77.13 56 77.8
Indication
Refractory 111 29 8 22.93 21 27.6
Recurrent 111 82 27 77.13 55 72.4
Prior therapy
Metronidazole 110 98 29 82.93 69 80.0 0.722
Vancomycin 109 109 35 100.03 74 98.7 0.493
Combination 109 31 12 34.33 19 25.7 0.352
Outcomes
Success 111 97 33 94.33 64 84.2 0.137
Recurrence by 6 m 99 16 7 203 9 14.1 0.443
Death 111 11 0 03 11 100.0 0.018
Adverse events 107 19 5 14.33 14 19.4 0.512
Mean SD Mean SD Sigma
Age (yr) 111 37.26 14.72 77.07 8.9 0.000
Charlson comorbidity score 81 1.29 1.95 6.35 2.3 0.000
Previous CDI episodes (n) 107 2.63 1.9 2.38 1.51 0.455
Time from 1st CDI (d) 89 198.75 279.04 102.68 112.19 0.024
Creatinine (mg/dL) 76 0.91 0.51 1.67 1.63 0.051
Albumin (mg/L) 54 3.51 0.99 3.17 0.69 0.153
WBC (103/dL) 76 11.33 90.36 14.78 19.86 0.468
1

Upper GI: Gastroscopy, nasogastric tube or through percutaneous endoscopic gastrostomy;

2

Percentages refer to the total number of subjects in the cohort;

3

Percentages refer to the number of subjects in the specific group. CDI: Clostridium difficile infection; IBD: Inflammatory bowel diseases; PPI: Proton pump inhibitor; GI: Gastrointestinal; FMT: Fecal microbiota implantation; IQR: Inter quartile range; WBC: White blood cells; Prior hospitalization: Hospitalization in the 3 mo prior to the FMT; Prior hospitalization: Antibiotics use in the 3 mo prior to the FMT.